07 July 2020 | News
Ms Stina Linge, as CEO to implement new plan at Lipidor to increase the rate of commercialization of its subsidiary Emollivet's products for animal applications
Photo Credit: Chalmers Ventures
Lipidor recently announced an updated plan to increase the rate of commercialization of its subsidiary Emollivet's products for animal applications. A licensing agreement formalizing the relationship between Emollivet and Lipidor has been signed and a directed new share issue proposal in Emollivet has been presented, for approval by Lipidor's EGM on 11 August.
The recruitment of a CEO to Emollivet is a key factor in being able to implement the announced plan. Chairman of Lipidor and also Emollivet, Fredrik Sjövall: “We are very pleased to have recruited Stina to Emollivet. Stina has solid experience of building and developing companies in the start-up phase from her time at Chalmers Ventures and will also contribute lots of energy to the continued commercialization of AKVANO-based animal care products.”